arrow
J

Jun Zhu

Fudan University Shanghai Cancer Center
H指数:26
被引数:2,643
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimal adjuvant radiotherapy strategy for cervical cancer: a multicenter database cohort study

宫颈癌最佳辅助放疗策略:一项多中心数据库队列研究

2025-11-060
PRE
Metabolic reprogramming and immunosenescence in colorectal cancer: mechanisms and therapeutic implications

代谢重编程和免疫衰老在结直肠癌中的作用:机制与治疗意义

2025-08-130
OA
The effectiveness of anti-PD-L1 treatment and the underlying regulatory mechanism in ovarian clear cell carcinoma

抗PD-L1治疗在卵巢透明细胞癌中的有效性与潜在调控机制

2025-08-120
OA
Development and validation of a prognostic nomogram for diffuse large B-cell lymphoma: a multicenter cohort study from Northern China

弥漫性大B细胞淋巴瘤预后Nomogram的开发与验证:一项来自中国北方的多中心队列研究

2025-05-230
PRE
Engineered Macrophage Exosomes Deliver Drug-Targeted Therapy for Breast Cancer

工程化巨噬细胞外泌体为乳腺癌提供药物靶向治疗

2024-11-070
OA
Clinical significance of intensity-modulated radiotherapy (IMRT) to the distant metastatic lymph nodes for metastatic cervical cancer
2024-09-200
OAAI
Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
2024-09-051
OAAI
BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)

BL-B01D1,一种EGFR x her3双特异性抗体偶联药物(ADC),用于局部晚期或转移性食管鳞状细胞癌(ESCC)患者的治疗。

2024-09-010
PRE
Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT)

东亚妇科肿瘤试验组 (EAGOT) 中卵巢癌的当前治疗策略

2024-01-014
OAAI
A relay-type innate immunity activation strategy involving water-soluble NIR-II AIEgen for boosted tumor photo-immunotherapy

涉及水溶性nir-ii AIEgen的中继型先天免疫激活策略,用于增强肿瘤光免疫疗法

2024-01-011
OAAI
Predicting Lymph Node Metastasis From Primary Cervical Squamous Cell Carcinoma Based on Deep Learning in Histopathologic Images

基于组织病理学图像深度学习的原发性宫颈鳞癌淋巴结转移预测

2023-12-015
PRE
Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
2023-11-011
PRE
KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer

KLF5促进卵巢癌肿瘤进展和Parp抑制剂耐药

2023-09-1313
OA
Developing a nomogram for preoperative prediction of cervical cancer lymph node metastasis by multiplex immunofluorescence
2023-05-303
OAAI
Prediction of Driver Gene Matching in Lung Cancer NOG/PDX Models Based on Artificial Intelligence
2022-08-011
OAAI
Mortality Rate of Lymphoma in China, 2013-2020
2022-06-076
OAAI
Prognostic Effect of Primary Recurrence Patterns in Squamous Cervical Carcinoma After Radical Surgery
2022-04-113
OAAI
Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
2021-11-2512
OAAI
Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
2021-11-0219
OAAI
Circ_0061140 knockdown inhibits tumorigenesis and improves PTX sensitivity by regulating miR-136/CBX2 axis in ovarian cancer

Circ_0061140敲低通过调节miR-136/CBX2轴抑制卵巢癌的肿瘤发生并改善PTX敏感性

2021-10-1420
OAAI